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Abstract
The protective effects of 5,6,7,8-tetrahydroneopterin (NH4) against radiation injury in mice were studied. (C57BL/6UA/
J)F1 (B6A) mice received a single whole-body irradiation dose of 200, 400, 700 or 800 cGy of X-rays. NH4 (30 mg/kg body
weight) or phosphate-buffered saline (PBS) was injected intraperitoneally into irradiated mice 10 min before and after the
irradiation and again after 6 h. All mice which received the 800 cGy radiation+PBS died between 8 and 11 days after the
treatment. In contrast, those which also received NH4 demonstrated a significantly prolonged survival time and 40% lived
more than 5 months. Total numbers of thymocytes and spleen cells on day 5 post-irradiation were dramatically reduced in
line with the radiation dose. The survival was significantly enhanced by NH4 in treated mice. The proliferation of spleen cells
in mice stimulated by concanavalin A (Con A) or lipopolysaccharide (LPS) was also greater in NH4 treated mice. The
immune response of survivors 5 months after 800 cGy+NH4 treatments, against Con A, LPS, allogenic mouse, and sheep red
blood cells had essentially recovered to the levels of normal mice. These results indicate that NH4 had an important role in
modifying radiation injury. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Neopterin (2-amino-6-(1,2,3-trihydroxypropyl)-
4(3H)-pteridinone) is a precursor of biopterin, which
is derived from guanosine triphosphate. It is now
generally accepted that neopterin is released from
monocytes/macrophages primarily under control of
interferon-Q produced by activated T cells [1^3]. It
has been observed that immune responses are invar-
iably accompanied by increased neopterin levels,
both in vivo and in vitro. In vitro release of neopter-
in from human peripheral blood mononuclear cells is
stimulated by alloantigens [4]. Elevated in vivo neo-
pterin excretion has been reported in patients in-
fected with bacterial or virus pathogens [5^7], with
autoimmune diseases [8^10] or in certain tumor-as-
sociated states [11^13]. Recently it was reported that
neopterin is an antioxidant in vitro and in vivo, and
that its reduced form 5,6,7,8-tetrahydroneopterin
(NH4), has an extremely high superoxide anion rad-
ical scavenging potential as an antioxidant [14].
It is believed that the major chemical lesion in-
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duced by radiation is produced by superoxide radi-
cals. It is well known that animals receiving a lethal
dose of radiation can survive when they are given an
injection of blood stem cells [15]. The weakest point
may be the survival of stem cells which are respon-
sible for the immune cells. Some studies have shown
that exogenously administered superoxide dismutase
(SOD) can protect against the e¡ects of ionizing ra-
diation both in vitro and in vivo [16^19]. However,
the relevance to the immune response in such ani-
mals has not been examined in detail. In the present
study we therefore examined the in£uence of the
SOD-like substance NH4 on post-irradiation injury
in mice. Particular attention was concentrated on the
functioning of the immune system.
2. Materials and methods
2.1. Animals and reagent
Eight week old (C57BL/6UA/J)F1 (B6A) and
BALB/c male mice were housed in a speci¢c patho-
gen-free facility at the Aichi Cancer Center Research
Institute. NH4 was purchased from Torii Pharm. Co.
(Tokyo, Japan).
2.2. Experimental protocol
Mice received a single whole-body irradiation of
200, 400, 700 or 800 cGy from an X-ray unit
(MBR1520R, Hitachi, Tokyo, Japan). A preliminary
experiment was performed to determine the most ef-
fective protocol of NH4 treatment (dosage and time
interval). For this NH4 (30 mg/kg body weight) was
dissolved in 0.2 ml PBS and intraperitoneally injected
into mice 10 min before and after irradiation, then
once again after 6 h. As a control, NH4 was injected
into non-irradiated mice at the same times. These
experiments were approved by our institution’s Ani-
mal Care Committee.
2.3. Flow cytometry
Spleen cells obtained from experimental mice were
counted and stained with monoclonal antibodies
(mAbs) against CD3, CD4, CD8, CD25, NK
(Phar-Mingen, San Diego, CA, USA), B220 (Caltag,
San Francisco, CA, USA) and F4/8 (Serotec, Ox-
ford, UK). mAbs were directly conjugated with
FITC or biotin. Phycoerythrin-streptavidin (Biome-
da, Foster City, CA, USA) was used as the second-
ary reagent. The cells were assayed using a FACScan
(Becton Dickinson, Mountain View, CA, USA).
2.4. Immune response
2.4.1. Concanavalin A (Con A) and
lipopolysaccharide (LPS) stimulation
Spleen cells were incubated in the presence of 2 Wg/
ml Con A or 20 Wg/ml LPS (Sigma, St. Louis, MO,
USA) for 3 days, followed by an 8 h incubation after
the addition of 18.5 kBq [3H]thymidine. The uptake
of [3H]thymidine was estimated with a scintillation
counter (Beckman Instruments, Palo Alto, CA).
2.4.2. Mixed lymphocyte culture (MLC) assay
Spleen cells (5U105) from experimental mice were
cocultured with irradiated (2400 cGy) spleen cells
(5U105) from B6A or BALB/c mice in 0.2 ml of
RPMI 1640 with 10% fetal calf serum for 4 days
at 37‡C, followed by 16 h incubation in the presence
of 18.5 kBq [3H]thymidine. The uptake of
[3H]thymidine was measured for the Con A response.
2.4.3. Plaque forming cell (PFC) assay
108 sheep red blood cells (SRBC) were injected
intravenously into the experimental mice. One week
later direct and indirect PFC assays were carried out
as described previously [20]. Statistical analysis was
performed using the Student’s t-test.
3. Results and discussion
3.1. E¡ects of NH4 against X-ray radiation injury
All 10 B6A mice which received a whole-body ir-
radiation (800 cGy X-ray) plus PBS injections died
between 8 and 11 days after the treatment (Fig. 1). In
contrast the 20 similarly irradiated mice treated with
NH4 demonstrated a signi¢cant prolongation of
their survival time (P6 0.01), and 40% of this group
survived for more than 5 months (Fig. 1). The result
clearly indicates that NH4 treatment protects against
lethal irradiation injury in mice.
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In order to determine e¡ects on the immune sys-
tem, the thymuses and spleens of mice irradiated
with 0^700 cGy with or without NH4 were removed
on day 5 post-irradiation, and total numbers of thy-
mocytes and spleen cells were counted. As shown in
Table 1, values were dramatically reduced with an
increase in the radiation dose. The survival ratios
of thymocytes and spleen cells were signi¢cantly im-
proved in NH4 treated mice when compared with
PBS-treated control mice. Assays of the subpopula-
tion of spleen cells by FACS revealed the relative
proportion of B cells (B220 cells) to be dramatically
decreased with the increase in the dose of X-rays in
both PBS and NH4 groups of mice (Table 2), com-
pared with non-irradiated mice (P6 0.01, at v 200
cGy), as previously demonstrated [21]. The propor-
tion of CD3 cells increased along with CD4 cells
(P6 0.05, at v 200 cGy), whereas CD8 cells re-
mained unchanged or slightly decreased in the both
groups. The results are in agreement with previous
reports [22], indicating that the murine spleen con-
tains a population of radioresistant CD4 cells. Sim-
ilarly CD25 cells, macrophages (F4/80) and NK
cells in the spleen constitute radioresistant popula-
tions (Table 2). There were no signi¢cant di¡erences
in the proportions of spleen cell subpopulations be-
tween PBS treated and NH4 treated mice, independ-
ent of the X-ray dose. Survival of each spleen cell
subpopulation in the 700 cGy+NH4 treated mice
was approximately 4-fold that in control mice (Ta-
bles 1 and 2).
To analyze the role of NH4 in lymphocyte re-
sponses, spleen cells obtained from post-irradiated
mice with or without NH4 treatments were stimu-
lated with Con A or LPS, for T cells and B cells,
respectively. The NH4 treated mice showed a much
higher [3H]thymidine uptake than the PBS treated
controls, the di¡erence becoming signi¢cant with
higher doses of irradiation (Table 3). Real numbers
of both T and B cells used in this analysis were al-
most the same for PBS and NH4 treated mice, as
shown in Table 2. Therefore, the value for prolifer-
ation stimulated by Con A or LPS re£ect real func-
tions of corresponding lymphocytes. The results sug-
gest that NH4 protects against radiation injury by
maintaining the capacity of T and B cells.
Recently Kojima et al. [14] reported that NH4 acts
as a superoxide anion scavenger using the xanthine/
xanthine oxidase and macrophage/phorbol myristate
acetate-reaction system. NH4 also inhibits oxidation
Fig. 1. Actuarial analysis of survival of experimental mice. Sur-
vival rate in mice receiving 800 cGy plus NH4 (999) and
PBS (- - -) di¡ered by log rank analysis (P6 0.01).
Table 1
Total number of thymocytes and spleen cells (U106) in B6A mice after varying doses of whole-body irradiation and NH4 or PBS
treatment
Cell population Reagent Dose of X-rays (cGy)
0 200 400 700
Thymocytes PBS 82 þ 22 13.3 þ 4.2 2.8 þ 2.2 0.38 þ 0.2
NH4 71 þ 25 21.4 þ 4.7** 5.9 þ 2.2* 1.4 þ 0.7**
Spleen cells PBS 140 þ 32 35.4 þ 4.9 4.6 þ 2.5 0.62 þ 0.2
NH4 137 þ 32 41.2 þ 8.6 8.4 þ 2.7* 2.4 þ 1.2**
Six mice were used for each group. Mice were irradiated with 0^700 cGy with PBS or NH4 treatments and their thymuses and spleen
were removed on day 5 post-irradiation. The data are mean values þ S.D. *P6 0.05; **P6 0.02, signi¢cantly di¡erent from the PBS
injected control.
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of linoleic acid about as e¡ectively as uric acid, and
suppresses alloxan-induced murine diabetes [14].
Such results and our present ¢ndings suggest that
NH4 may play an important role as an SOD-like
substance, scavenging superoxide anion radicals.
3.2. Immune functions of surviving mice after
irradiation and NH4 treatments
40% of B6A mice receiving 800 cGy X-ray irradi-
ation with NH4 treatments lived for more than
5 months (Fig. 1). Spleen cell number (4.7 þ
1.3U107, mean þ S.D.) of survivors (n = 7) was sig-
ni¢cantly (P6 0.01) lower than that (8.4 þ 0.8U107)
of normal mice (n = 6). However, the distribution of
surface markers (B220, CD3, CD4 and CD25) was
quite similar between the groups (data not shown).
Next we examined the immune functions of survivors
with several stimulators. As shown in Fig. 2A, with a
T cell speci¢c stimulus by Con A, the response of
spleen cells from survivors was somewhat lower
than that of normal mice, but nevertheless appreci-
Table 2
Distribution (%) of subpopulations of spleen cells in B6A mice after varying doses of whole-body irradiation and NH4 or PBS treat-
ment
Surface marker Reagent Dose of X-rays (cGy)
0 200 400 700
B220 PBS 52.5 þ 4.9 33.6 + 4.1*** 23.3 + 6.6*** 8.9 + 4.0***
NH4 52.5 þ 3.7 30.2 þ 5.0*** 19.5 þ 6.1*** 10.8 þ 5.5***
CD3 PBS 33.2 þ 4.1 40.8 þ 5.6 45.6 þ 9.9* 67.1 þ 12***
NH4 34.1 þ 4.0 40.0 þ 5.5 44.2 þ 9.1 65.1 þ 11***
CD4 PBS 19.3 þ 2.1 25.4 þ 3.0*** 35.1 þ 11** 59.5 þ 10***
NH4 20.3 þ 2.0 26.1 þ 4.6* 34.6 þ 12* 51.1 þ 12***
CD8 PBS 12.8 þ 1.5 13.1 þ 2.0 9.1 þ 3.1 7.5 þ 4.5*
NH4 12.3 þ 1.6 13.6 þ 1.1 8.7 þ 2.5* 8.5 þ 5.5
CD25 PBS 2.7 þ 0.6 3.5 þ 0.5 3.0 þ 0.4 4.9 þ 1.8*
NH4 2.8 þ 0.4 3.5 þ 0.6 3.4 þ 0.6 5.4 þ 2.0*
F4/80 PBS 3.5 þ 0.5 5.1 þ 0.8*** 6.2 þ 0.5*** 6.6 þ 2.4*
NH4 3.3 þ 0.7 7.3 þ 1.8*** 6.8 þ 0.7*** 7.0 þ 2.1***
NK PBS 1.0 þ 0.3 1.6 þ 0.5 3.1 þ 0.9*** 3.9 þ 1.0***
NH4 1.3 þ 0.4 1.5 þ 0.3* 3.0 þ 0.8*** 4.4 þ 1.9***
Five mice were used for each group. Mice were irradiated with 0^700 cGy with PBS or NH4 treatments and their spleen were re-
moved on day 5 post-irradiation. The data are means þ S.D. *P6 0.05; **P6 0.02; ***P6 0.01, signi¢cantly di¡erent from the non-
irradiated mice with PBS treatment.
Table 3
Proliferative response (U103 cpm) to Con A or LPS administration
Stimulator Reagent Dose of X-rays (cGy)
0 200 400 700
Con A PBS 14.7 þ 3.9 11.4 þ 2.2 10.5 þ 2.8 0.6 þ 0.1
NH4 16.9 þ 5.0 17.6 þ 3.3* 17.3 þ 3.0* 1.6 þ 0.3***
LPS PBS 1.9 þ 0.5 1.5 þ 0.3 0.48 þ 0.11 0.04 þ 0.01
NH4 2.2 þ 0.6 2.1 þ 0.4 1.05 þ 0.29** 0.21 þ 0.09**
Four mice were used for each group. Mice were irradiated with 700 cGy with PBS or NH4 treatments and their spleen were removed
on day 5 post-irradiation. Unfractionated spleen cells (1U105) were cultured in the presence of Con A or LPS for 72 hours, then
pulsed with 0.5 WCi [3H]thymidine, 8 h prior to termination of culture. The data are mean þ S.D. *P6 0.05; **P6 0.02; ***P6 0.01,
signi¢cantly di¡erent from the PBS injected control.
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able, while the response to B cell speci¢c stimulus by
LPS was similar in both groups (Fig. 2B). The pro-
liferative response in MLC against allogenic BALB/c
spleen cells showed that the survivors were less reac-
tive than the controls (Fig. 2C). In response to
SRBC, survivors yielded more IgM and IgG produc-
ing cells than the controls (Fig. 2D). In addition, the
immune functions of mice treated with NH4 alone
(n = 6) were quite similar to those of the normal mice
(data not shown). These results indicate that immune
function, especially T cell and B cell functions, had
almost recovered from lethal irradiation to normal
levels due to the NH4 treatment.
The formation of reactive oxygen species following
X-ray or long-wavelength ultraviolet light (UV-A)
irradiation is thought to be a major determinant of
tissue damage. Neopterin drastically enhanced the
UV-A induced cell damage in vitro, whereas NH4
abolished the damage [23]. NH4 is a reduced form
of neopterin, and the antioxidative activity of NH4
has been reported [14]. Transient activation of the
DNA binding activity of nuclear factor-UB (NF-
UB) has been reported after exposure in vitro to Q-
or X-rays [24]. Recent reports with knock-out mouse
models have shown that the lack of RelA, a subunit
of NF-UB, results in acute cell death by apoptosis in
the embryonic liver [25,26]. Activation of NF-UB has
been shown to play a protective role against pro-
grammed cell death [27^29]. Recent papers indicated
a potential role for neopterin derivatives in oxygen
radical mediated processes [30^34], and neopterin
and its reduced forms were shown to be involved
in redox signaling and the activation of transcription
factors NF-UB and AP-1 [35,36]. In our study the
administration of NH4 in mice before and after X-
ray irradiation may promote further activation of
transcription factors for the protection from radia-
tion injury.
In addition, the neurohormone melatonin was
found to be a potent endogenous hydroxyl radical
scavenger [37]. For example, melatonin protects lym-
phocytes from radiation induced chromosome dam-
Fig. 2. Immune response in surviving mice after irradiation and NH4 treatments. In all assays 7-month-old mice receiving 800 cGy
were used. In all panels closed circles represent results with survivors and open circles with control B6A mice. (A) Proliferative re-
sponse to Con A. Spleen cells were cultured in the presence of Con A. (B) Proliferative response to LPS. Spleen cells were cultured in
the presence of LPS. (C) Proliferative response to allogeneic spleen cells in MLC. Spleen cells were cocultured with irradiated spleen
cells from allogeneic BALB/c or syngeneic B6A mice. (D) PFC response to SRBC. Mice were immunized with SRBC, and the num-
bers of PFCs in their spleens were enumerated by direct assay (D) for cells producing IgM antibody and by indirect assay (I) for cells
producing IgG and IgM antibodies.
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age [38]. Melatonin appears to activate at least one
cellular enzymatic antioxidant defense mechanism,
the induction of glutathione peroxidase [39]. Further-
more, melatonin may stimulate some important anti-
oxidative enzymes, such as superoxide dismutase
[37]. The possible interaction between melatonin
and pteridine metabolism is an interesting study for
the future.
In conclusion, NH4 may be useful as a therapeutic
agent against diseases in which active oxygen species
act as potent pathogenic factors, such as with post-
radiation injury. In particular, NH4 might ¢nd ap-
plication in combination with radiation therapy for
human cancers with poor blood vessel formation
such as some pancreatic carcinomas.
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